As the combination treatment tends to be the most promising solution suggested by the latest AACE/ACE clinical practice guidelines, we proposed that the combined liraglutide and insulin treatment might alleviate insulin aggravated hepatic steatosis. This evidence concerns the gene INS and fatty liver disease.